Delving into the Latest Updates on IQVIA RDS (Shanghai) Co. Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

RT(Viral reverse transcriptase)	1

这项关键性随机双盲研究的目的是在正在接受ARB治疗的成人FSGS患者中评价DMX-200 120 mg每日两次（BID）给药与安慰剂相比在104周治疗期内的有效性和安全性。双盲期之后将为开放性扩展期（OLE）,旨在评估DMX-200至多额外2年治疗的长期有效性和安全性。

[Translation]

The purpose of this pivotal, randomized, double-blind study is to evaluate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared to placebo over a 104-week treatment period in adult patients with FSGS who are currently receiving ARB therapy. The double-blind period will be followed by an open-label extension period (OLE) to evaluate the long-term efficacy and safety of DMX-200 for up to an additional 2 years of treatment.

Start Date15 Aug 2024

Sponsor / Collaborator

IQVIA RDS (Shanghai) Co. Ltd.

[+2]

CTR20242077 / RecruitingPhase 1

一项在中国晚期实体瘤受试者中评估 SGN-B6A 安全性和药代动力学的开放性、I 期研究

[Translation] An open-label, Phase I study evaluating the safety and pharmacokinetics of SGN-B6A in Chinese subjects with advanced solid tumors

主要目的：评估SGN-B6A单药治疗在中国晚期实体瘤患者中的安全性和耐受性。次要目的：评估SGN-B6A的PK，免疫原性。探索性目的：评估SGN-B6A的抗肿瘤活性。

[Translation]

Primary objective: To evaluate the safety and tolerability of SGN-B6A monotherapy in Chinese patients with advanced solid tumors. Secondary objective: To evaluate the PK and immunogenicity of SGN-B6A. Exploratory objective: To evaluate the anti-tumor activity of SGN-B6A.

Start Date08 Aug 2024

Sponsor / Collaborator

BSP Pharmaceuticals SpA

[+2]

CTR20232946 / RecruitingPhase 3

一项在中度至重度活动性溃疡性结肠炎受试者中评价ABX464 25 mg或 50 mg 每日一次维持治疗的长期有效性和安全性的随机、双盲、多中心、3 期研究。

[Translation] A randomized, double-blind, multicenter, Phase 3 study evaluating the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as maintenance therapy in subjects with moderately to severely active ulcerative colitis.

主要目的：评价ABX464相较于安慰剂在临床缓解方面的有效性。

[Translation]

Primary objective: To evaluate the effectiveness of ABX464 compared with placebo in achieving clinical remission.

Start Date03 Jun 2024

Sponsor / Collaborator

Creapharm Clinical Supplies SAS

[+3]

100 Clinical Results associated with IQVIA RDS (Shanghai) Co. Ltd.

Login to view more data

0 Patents (Medical) associated with IQVIA RDS (Shanghai) Co. Ltd.

Login to view more data

100 Deals associated with IQVIA RDS (Shanghai) Co. Ltd.

Login to view more data

100 Translational Medicine associated with IQVIA RDS (Shanghai) Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Obefazimod ( RT )	Ulcerative colitis, active severe More	Phase 3
oplunofusp ( sialic acid )	Parainfluenzae virus infection More	Discontinued
Ripretinib ( PDGFRα x c-Kit )	Gastrointestinal Stromal Tumors More	Pending